Potential loss of prognostic significance of minimal residual
disease assessment after R-CHOP-based induction in elderly
patients with mantle cell lymphoma in the era of rituximab
maintenance

J 2018

Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance

KLENER, Pavel, Eva FRONKOVA, Marketa KALINOVA, David BELADA, Kristina FORSTEROVA et. al.

Basic information

Original name

Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance

Authors

KLENER, Pavel (203 Czech Republic, guarantor), Eva FRONKOVA (203 Czech Republic), Marketa KALINOVA (203 Czech Republic), David BELADA (203 Czech Republic), Kristina FORSTEROVA (203 Czech Republic), Robert PYTLIK (203 Czech Republic), Petra BLAHOVCOVA (203 Czech Republic), Martin SIMKOVIC (203 Czech Republic), David ŠÁLEK (203 Czech Republic, belonging to the institution), Heidi MOCIKOVA (203 Czech Republic), Vit PROCHAZKA (203 Czech Republic), Andrea JANIKOVA (203 Czech Republic), Martina VASKOVA (203 Czech Republic), Ester MEJSTRIKOVA (203 Czech Republic), Roman KODET (203 Czech Republic), Jan TRKA (203 Czech Republic) and Marek TRNENY (203 Czech Republic)

Edition

Hematological Oncology, MALDEN, USA, WILEY-BLACKWELL, 2018, 0278-0232

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 3.439

RIV identification code

RIV/00216224:14110/18:00105802

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1002/hon.2550

UT WoS

000452625700007

Keywords in English

elderly patients; maintenance rituximab; mantle cell lymphoma; minimal residual disease; PET-CT

Abstract

V originále

Rituximab maintenance (RM) prolongs survival of elderly patients with mantle cell lymphoma (MCL). Persistent minimal residual disease (MRD) after induction repeatedly correlated with shorter progression-free survival (PFS). However, none of the published studies analyzed patients treated with RM. The main purpose was to analyze prognostic significance of MRD in the elderly patients with newly diagnosed MCL treated according to the recently published observational trial protocol (alternation of R-CHOP and R-cytarabine, 3 + 3 cycles, GovTrial number NCT03054883) at the centers that implemented RM. Minimal residual disease was evaluated by a EuroMRD standardized real-time PCR approach after 3 and 6 cycles of the induction therapy. Prognostic significance of MRD was analyzed in a subcohort of patients treated at the centers that implemented RM as a standard approach. Bone marrow proved to be a significantly more sensitive source for MRD detection than peripheral blood. In either compartment MRD (positive versus negative) after 3 or 6 cycles of the induction therapy did not correlate with PFS. The observed loss of prognostic significance of MRD after the R-CHOP-based induction appears to be a consequence of RM immune control over the residual lymphoma.

Citovat

KLENER, Pavel, Eva FRONKOVA, Marketa KALINOVA, David BELADA, Kristina FORSTEROVA, Robert PYTLIK, Petra BLAHOVCOVA, Martin SIMKOVIC, David ŠÁLEK, Heidi MOCIKOVA, Vit PROCHAZKA, Andrea JANIKOVA, Martina VASKOVA, Ester MEJSTRIKOVA, Roman KODET, Jan TRKA and Marek TRNENY. Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance. Hematological Oncology. MALDEN, USA: WILEY-BLACKWELL, 2018, vol. 36, No 5, p. 773-778. ISSN 0278-0232. Available from: https://dx.doi.org/10.1002/hon.2550.

@article{1489197,
   author = {Klener, Pavel and Fronkova, Eva and Kalinova, Marketa and Belada, David and Forsterova, Kristina and Pytlik, Robert and Blahovcova, Petra and Simkovic, Martin and Šálek, David and Mocikova, Heidi and Prochazka, Vit and Janikova, Andrea and Vaskova, Martina and Mejstrikova, Ester and Kodet, Roman and Trka, Jan and Trneny, Marek},
   article_location = {MALDEN, USA},
   article_number = {5},
   doi = {http://dx.doi.org/10.1002/hon.2550},
   keywords = {elderly patients; maintenance rituximab; mantle cell lymphoma; minimal residual disease; PET-CT},
   language = {eng},
   issn = {0278-0232},
   journal = {Hematological Oncology},
   title = {Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance},
   volume = {36},
   year = {2018}
}

TY  - JOUR
ID  - 1489197
AU  - Klener, Pavel - Fronkova, Eva - Kalinova, Marketa - Belada, David - Forsterova, Kristina - Pytlik, Robert - Blahovcova, Petra - Simkovic, Martin - Šálek, David - Mocikova, Heidi - Prochazka, Vit - Janikova, Andrea - Vaskova, Martina - Mejstrikova, Ester - Kodet, Roman - Trka, Jan - Trneny, Marek
PY  - 2018
TI  - Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance
JF  - Hematological Oncology
VL  - 36
IS  - 5
SP  - 773-778
EP  - 773-778
PB  - WILEY-BLACKWELL
SN  - 02780232
KW  - elderly patients
KW  - maintenance rituximab
KW  - mantle cell lymphoma
KW  - minimal residual disease
KW  - PET-CT
N2  - Rituximab maintenance (RM) prolongs survival of elderly patients with mantle cell lymphoma (MCL). Persistent minimal residual disease (MRD) after induction repeatedly correlated with shorter progression-free survival (PFS). However, none of the published studies analyzed patients treated with RM. The main purpose was to analyze prognostic significance of MRD in the elderly patients with newly diagnosed MCL treated according to the recently published observational trial protocol (alternation of R-CHOP and R-cytarabine, 3 + 3 cycles, GovTrial number NCT03054883) at the centers that implemented RM. Minimal residual disease was evaluated by a EuroMRD standardized real-time PCR approach after 3 and 6 cycles of the induction therapy. Prognostic significance of MRD was analyzed in a subcohort of patients treated at the centers that implemented RM as a standard approach. Bone marrow proved to be a significantly more sensitive source for MRD detection than peripheral blood. In either compartment MRD (positive versus negative) after 3 or 6 cycles of the induction therapy did not correlate with PFS. The observed loss of prognostic significance of MRD after the R-CHOP-based induction appears to be a consequence of RM immune control over the residual lymphoma.
ER  -

KLENER, Pavel, Eva FRONKOVA, Marketa KALINOVA, David BELADA, Kristina FORSTEROVA, Robert PYTLIK, Petra BLAHOVCOVA, Martin SIMKOVIC, David ŠÁLEK, Heidi MOCIKOVA, Vit PROCHAZKA, Andrea JANIKOVA, Martina VASKOVA, Ester MEJSTRIKOVA, Roman KODET, Jan TRKA and Marek TRNENY. Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance. \textit{Hematological Oncology}. MALDEN, USA: WILEY-BLACKWELL, 2018, vol.~36, No~5, p.~773-778. ISSN~0278-0232. Available from: https://dx.doi.org/10.1002/hon.2550.

Detailed Information on Publication Record